News|Articles|November 17, 2026

FDA Grants Accelerated Approval to Neladalkib in Pretreated ALK+ NSCLC

Author(s)Alex Biese
Fact checked by: By ONN Staff

Neladalkib produced response rates of 49% after alectinib and 32% after multiple ALK TKIs plus chemotherapy in the ALKOVE-1 trial.

The FDA has granted accelerated approval to neladalkib (Nelkarmi; Nuvalent, Inc.), a kinase inhibitor, for adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) previously treated with alectinib, or with 2 or more ALK tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy.1

The November 17, 2026, decision rests on response rate and duration of response (DOR) from the ALKOVE-1 trial, and the label carries warnings for hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase (CPK) elevation, and embryo-fetal toxicity that will shape monitoring plans.1

How was neladalkib studied in ALKOVE-1?

Efficacy was evaluated in the phase 1/2 ALKOVE-1 trial (NCT05384626), a multicenter, single-arm, open-label, multicohort study.1,2 The FDA's review drew on 2 cohorts:

  • Cohort 1: 67 patients who had received 1 prior ALK TKI, alectinib
  • Cohort 2: 155 patients who had received 2 or more prior ALK TKIs and platinum-based chemotherapy

The major efficacy outcome measures were confirmed overall response rate (ORR) and DOR, assessed by blinded independent central review per RECIST v1.1.1

Neladalkib is a brain-penetrant, ALK-selective inhibitor designed to remain active in tumors that have developed resistance to first-, second-, and third-generation ALK inhibitors, including tumors with single or compound ALK resistance mutations such as G1202R.2 It was also designed to spare the TRK kinase family, which may lower the risk of central nervous system adverse effects associated with dual TRK/ALK inhibition, as Oncology Nursing News previously reported when Nuvalent submitted its new drug application in April 2026.3

What response rates did neladalkib produce?

Responses were seen in both cohorts1:

  • Cohort 1 (prior alectinib): ORR was 49% (95% CI, 37%-62%). Among responders, 76% had a DOR of at least 6 months and 52% had a DOR of at least 12 months.
  • Cohort 2 (2 or more prior ALK TKIs plus chemotherapy): ORR was 32% (95% CI, 24%-40%). Among responders, 69% had a DOR of at least 6 months and 51% had a DOR of at least 12 months.

When topline ALKOVE-1 data were announced in November 2025, Alice T. Shaw, MD, PhD, a thoracic oncologist at Dana-Farber Cancer Institute and ALKOVE-1 investigator, said that in treating ALK-positive lung cancer, "our goal is not only to help patients live longer, but also to help them live well with their disease."4

What adverse reactions should nurses anticipate?

The most common adverse reactions, occurring in at least 20% of patients, were hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, and fatigue.1 Warnings and precautions cover hepatotoxicity, renal toxicity, ocular toxicity, CPK elevation, and embryo-fetal toxicity.1 Individual adverse reaction rates and dose-modification guidance will appear in the full prescribing information, which the FDA said will be posted to Drugs@FDA.1

How is neladalkib dosed?

The recommended dose is 150 mg orally once daily, with or without food, taken at the same time every day until disease progression or unacceptable toxicity.1

What comes next for neladalkib?

Under the FDA's accelerated approval pathway, continued approval may be contingent on verification of clinical benefit in confirmatory trials.5 The application received priority review, breakthrough therapy designation, and orphan drug designation.1

In the frontline setting, the randomized, open-label phase 3 ALKAZAR trial (NCT06765109) is comparing neladalkib with alectinib in approximately 450 patients with treatment-naive, ALK-positive advanced NSCLC, with progression-free survival as the primary end point.6

What are the key takeaways for oncology nurses?

  • Confirm treatment history: the indication covers patients previously treated with alectinib, or with 2 or more ALK TKIs plus platinum-based chemotherapy.1
  • Plan laboratory monitoring around the labeled warnings, including liver function, renal function, and CPK, following the full prescribing information.1
  • Ask about vision changes at visits, given the ocular toxicity warning.1
  • Prepare patients for constipation, taste changes, neuropathy, edema, fatigue, and musculoskeletal pain, and encourage early reporting.1
  • Counsel patients of reproductive potential about embryo-fetal toxicity.1
  • Reinforce once-daily dosing at the same time each day, with or without food.1
  • Support shared decision-making by explaining that the approval is based on response rate and DOR, with confirmatory data still to come.1,5

References

1. FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer. FDA. November 17, 2026. Accessed November 17, 2026. https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-neladalkib-previously-treated-locally-advanced-or-metastatic-alk

2. Nuvalent announces key program and business updates, strengthening foundation for global leadership in ROS1- and ALK-positive NSCLC. News release. Nuvalent, Inc. May 27, 2026. Accessed November 17, 2026. https://investors.nuvalent.com/2026-05-27-Nuvalent-Announces-Key-Program-and-Business-Updates,-Strengthening-Foundation-for-Global-Leadership-in-ROS1-and-ALK-positive-NSCLC

3. Feldman S. Nuvalent submits NDA for neladalkib in ALK+ NSCLC after TKIs. Oncology Nursing News. April 7, 2026. Accessed November 17, 2026. https://www.oncnursingnews.com/view/nuvalent-submits-nda-for-neladalkib-in-alk-nsclc-after-tkis

4. Nuvalent announces positive topline pivotal data from ALKOVE-1 clinical trial of neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC. News release. Nuvalent, Inc. November 17, 2025. Accessed November 17, 2026. https://investors.nuvalent.com/2025-11-17-Nuvalent-Announces-Positive-Topline-Pivotal-Data-from-ALKOVE-1-Clinical-Trial-of-Neladalkib-for-TKI-Pre-treated-Patients-with-Advanced-ALK-positive-NSCLC

5. Expedited programs for serious conditions—drugs and biologics. Guidance for industry. FDA. May 2014. Accessed November 17, 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics

6. Neladalkib (NVL-655) for TKI-naive patients with advanced ALK-positive NSCLC (ALKAZAR). ClinicalTrials.gov identifier: NCT06765109. Accessed November 17, 2026. https://clinicaltrials.gov/study/NCT06765109


Related to this article